Redeye provides its initial take on Lifco’s Q3 2025 report, which aligned with our estimates.
Redeye returns with a more in-depth take on the Q3 report.
Redeye reviews Alligator Bioscience’s Q3 report 2025.
While Fiskars' adjusted EBIT fell short of Modular Finance consensus, broad-based top-line growth is...
Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimat...
* Small negative sales estimate revisions * Long term outlook is encouraging * Reiterate fair value ...
Redeye has a positive take on the news that Egetis has been granted a rolling NDA review based on cu...
Redeye comments on Invisio’s Q3-results which were in line with preliminary results announced on Oct...
* Rec. PTP -4% vs ABGSCe * Occupancy flat q-o-q, as are values * Share to underperform the sector to...
* Q3 EBITDA NOK 14m vs ABGSCe NOK 9m * Awaiting stabilised markets * Only minor adjustments to estim...
SRV's net sales in Q3 amounted to EUR 159.7m, quite in line with our estimate of EUR 163.
* A new divestment by Qben Infra... * ...selling Kvalitetsbygg R AB.
Fiskars Q3 adjusted EBIT of EUR 13.9m came 24% (EUR 4.
Redeye is optimistic about the deal with Biossil worth up to USD60m.
Redeye notes that Enea’s Q3 2025 report was lacklustre, with reported sales 9% below Redeye’s foreca...
